Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.

Karisa C Schreck Strowd Re Louis Burt Nabors Benjamin M Ellingson Michael Chang Sze Kiat Tan Zied Abdullaev Rust Turakulov Kenneth D Aldape Neeraja Danda Serena Desideri Joy Fisher Michaella Iacoboni Trisha Surakus Michelle A Rudek Chetan Bettegowda Stuart A Grossman Xiaobu Ye

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Encorafenib and binimetinib exhibit positive tumor responses in patients with recurrent BRAF-V600E mutant HGG in this small series, warranting therapeutic consideration. Although toxicity remains a concern for BRAF-targeted therapies, no new safety signal was observed in these patients.

Keyphrases

wild type
high grade
end stage renal disease
metastatic colorectal cancer
newly diagnosed
chronic kidney disease
ejection fraction
oxidative stress
prognostic factors
low grade